Benedetto Grimaldi
Has grant
Senior Researcher
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Therapeutic clock
Open Date: 2013-02-01
Close Date: 2015-02-01
Grant: Close
Circadian nuclear receptor REV-ERBbeta and autophagy: metabolic and molecular links for novel anticancer combined strategy
Open Date:
Close Date:
Articles (4)
Year:
2026
Year:
2024
Year:
2024
Background EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. Methods We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of EZH2i on both cellular- and cell-free-H3K27me3 levels. We measured effects of carboplatin with/without EZH2i on AVPC cell viability (IC 50 ). We studied how EZH2i modulate gene expression (RNA Seq). Results EZH2 was significantly up-regulated in AVPC vs other prostate cancer types. EZH2i reduced both cellular and cell free-H3K27me3 levels. EZH2i significantly reduced carboplatin IC 50 . EZH2i reduced the expression of DNA repair and increased the expression of pro-apoptotic genes. Article Highlights Polycomb-mediated gene silencing promotes prostate cancer progression Aggressive-variant prostate cancers (AVPCs) are characterized by increased activity of the Polycomb-Repressive Complex 2 (PRC2) Here we show that PRC2 inhibitors are scarcely effective as monotherapy in ACPC cells However the combination of PRC2 inhibitors and carboplatin is highly synergistic RNA Seq studies revealed that PRC2 inhibitors enhance carboplatin activity by modulating several key pathways, including DNA repair and apoptosis.
Year:
2024
Collaborators (6)
Shusuke Akamatsu
Professor
Nagoya University Hospital
Marc Panosetti
Non-Stipendiary Lecturer in Organic Chemistry
University of Oxford
Sushila Rigas
Open University
Elena Jachetti
Researcher (non-academic)
Fondazione IRCCS Istituto Nazionale dei Tumori
Francesco Crea
Professor (Chair) of Cancer Pharmacology
Open University
Maria Duca
Université Côte d'Azur
Make your next move.
Prepare your application
Review drafts before you send them.